SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Intel Trader who wrote (5112)8/12/1998 8:31:00 AM
From: margie  Respond to of 6136
 
Yeah!! Agouron's Viracept Receives Marketing Approval in Canada.
August 12. the Notice of Com;iancd allows Agouron to market Viracept in Canada for the treatment of HIV infecton in combination with reverse transcriptase inhibitors. the indication is based on analyses of surrogate endpoints in clinical studies up to 48 weeks.
Viracept is the first protease inhibitor to receive simultaneous approval of an indication for both adults and children in Canada.
Viracept has been available in Canada without charge since May 1997 ...HIV infected children aged two to 12 with no alternatives have received the drug through the Emergency Drug Release Program.



To: Intel Trader who wrote (5112)8/12/1998 9:58:00 AM
From: Peter Singleton  Read Replies (3) | Respond to of 6136
 
IT,

<<

I wouldn't do anything drastic if I were the little guy (and like many
of you, I am), but do do what makes you comfortable in your investment
decisions.>>

Wise counsel. I think the first task is to do no harm while you assess the macro-market environment and your own situation. On the one hand, don't extend yourself further (*don't* add to your margin, for example). On the other hand, don't panic. Staying cool at a time like this will be an asset.

But be prepared to make substantive decisions on your portfolio and its risk profile, if your assessment of the macro-market environment warrants doing so. This is for real.

just my two cents ...

Peter